Novartis CEO

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities 28 Oct 2026, 05:00 PM IST

Novartis Stands by Avidity Deal After $1.9 Billion Del-desiran Setback

Novartis is absorbing a steep charge after the failure of del-desiran, but management is signaling that the setback does not alter its confidence in the broader Avidity transaction. The company also lifted its annual profit guidance, underscoring a message of operational resilience even as clinical-trial volatility weighs on near-term earnings. Investors are now weighing whether Novartis can keep executing its pipeline strategy while defending the long-term case for external innovation.

By RDU Global Wire5 min read

Global Health & Biotech04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With China’s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmaker’s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

6 min readRead →

👤 About this Entity

Political leaders, ministers, corporate executives, judges, athletes and creators. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Novartis CEO:

Washington, D.C.(1)Novartis(1)Avidity(1)